ABIVAX Shares Close at €81.60, Confirming Weekly Momentum of +3.95%
ABIVAX shares ended higher this Monday, October 27, gaining 3.03% to close at €81.60. The stock recorded the strongest performance in the SBF 120 at the close of the Paris markets. This increase occurs in a context where the biotech stock has shown remarkable gains over more than a year, reflecting a spectacular trajectory since the beginning of the fiscal year.
Detailed Stock Performance
ABIVAX's share price settled at €81.60 at the close, marking a rise of 3.03% compared to the previous day when the stock was priced at €79.20. On a weekly basis, the stock has accumulated a gain of 3.95%, while its quarterly performance has reached 43.16% since the end of July. Since the start of 2025, the stock has soared by 775.5%, significantly outperforming the French equity markets. For comparison, the CAC 40 index has increased by 9.89% over the same period, and the SBF 120 showed a limited rise this Monday with a gain of 0.16%. However, trading volumes remain limited as only 0.1% of the capital was traded in today's transactions, indicating measured market activity despite the upward movement. Analyst consensus gives a target price of €97.87 in three months, implying a potential appreciation of 23.58% from current levels.
Continued Positive Developments
The stock's progression follows a series of positive announcements made in early October. On October 6, ABIVAX released encouraging Phase 3 data for obefazimodi, its flagship therapeutic candidate, which supported the stock's performance. Beyond these elements, the context is also marked by the recent notification of a threshold crossing: JP Morgan Chase declared it had exceeded 5% of the voting rights of the biotech company in early October, reflecting sustained interest from institutional investors in the case. These various elements fuel a positive dynamic, even though market flows remain relatively concentrated.
Technical Analysis Overview
Technically, the stock is now clearly above its 50-day moving average, set at €72.24, and its 200-day moving average, established at €27.54. This configuration suggests sustained positive momentum. The Relative Strength Index (RSI) is at 56, indicating a neutral stance without clear overbought conditions. The MACD oscillator shows a slight negative divergence with a gap of -0.06 points, though the signal remains well above the MACD line. The one-month measured volatility is at 12.17%, reflecting the stock's fluctuations. The Bollinger Bands frame the price between €85.24 as the upper resistance and €68.93 as the lower support, the latter level being a key reference in case of bearish consolidation.
